*Diffusion Pharmaceuticals is actively evaluating trans sodium crocetinate (TSC)’s potential to improve the availability of oxygen in patients with COVID-19, building upon data from prior clinical studies in peripheral artery disease and glioblastoma multiform (GBM) brain cancer.